- Conditions
- Covid19
- Interventions
- BAMLANIVIMAB, CASIRIVIMAB, IMDEVIMAB
- Biological
- Lead sponsor
- Sohail Rao
- Other
- Eligibility
- 12 Years and older
- Enrollment
- 1,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 3
- States / cities
- Edinburg, Texas • Rio Grande City, Texas
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 60
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Acute Lymphoblastic Leukemia
- Interventions
- MOR00208 (formerly Xmab5574)
- Drug
- Lead sponsor
- MorphoSys AG
- Industry
- Eligibility
- 16 Years and older
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2015
- U.S. locations
- 3
- States / cities
- Columbus, Ohio • Memphis, Tennessee • Houston, Texas
- Conditions
- Merkel Cell Carcinoma
- Interventions
- Avelumab, N-803, haNK™
- Biological
- Lead sponsor
- ImmunityBio, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 5
- States / cities
- San Francisco, California • Miami, Florida • St Louis, Missouri + 1 more
- Conditions
- Lymphoma, Multiple Myeloma, Acute Myeloid Leukemia, Diffuse Large B-Cell Lymphoma
- Interventions
- Maplirpacept (PF-07901801), Azacitidine, Venetoclax, Carfilzomib, Dexamethasone, Anti-CD20 Targeting agent, Isatuximab
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 189 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2024
- U.S. locations
- 62
- States / cities
- Los Angeles, California • Pasadena, California • Denver, Colorado + 29 more
- Conditions
- Non Small Cell Lung Cancer
- Interventions
- Nab-paclitaxel, Cisplatin, 5Fluorouracil, Cyclophosphamide, ETBX-011, ETBX-051, ETBX-061, GI-4000, GI-6301, Aldoxorubicin, Avelumab, ALT-803, haNK, Docetaxel, carboplatin
- Drug · Biological
- Lead sponsor
- ImmunityBio, Inc.
- Industry
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018
- U.S. locations
- 1
- States / cities
- El Segundo, California
- Conditions
- Warm Autoimmune Hemolytic Anemia
- Interventions
- ALXN1830, Placebo
- Drug
- Lead sponsor
- Alexion Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 1
- States / cities
- Riverside, California
- Conditions
- Malignant Solid Tumor
- Interventions
- AVID200
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 2
- States / cities
- Grand Rapids, Michigan • Houston, Texas
- Conditions
- Pancreatic Cancer Metastatic, Pancreatic Adenocarcinoma Metastatic
- Interventions
- Botensilimab, Balstilimab, Chloroquine Phosphate, Celecoxib, Nab paclitaxel, Gemcitabine, Cisplatin
- Drug
- Lead sponsor
- HonorHealth Research Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025
- U.S. locations
- 1
- States / cities
- Scottsdale, Arizona
- Conditions
- Leukaemia, Lymphocytic, Chronic
- Interventions
- OFC Infusion, FC infusion
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 365 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2017
- U.S. locations
- 6
- States / cities
- Boca Raton, Florida • Chicago, Illinois • Clinton, Maryland + 3 more
- Conditions
- Advanced Solid Tumor, Metastatic Solid Tumor, Soft Tissue Sarcoma (STS), Platinum-resistant Ovarian Cancer (PROC), Hepatocellular Carcinoma (HCC), Colorectal Cancer (CRC), HER2 Negative Breast Cancer, Cutaneous Melanoma, Renal Cell Carcinoma (RCC)
- Interventions
- GI-102 subcutaneous (SC), GI-102, doxorubicin, paclitaxel, bevacizumab, eribulin, trastuzumab deruxtecan (T-DXd), pembrolizumab
- Drug
- Lead sponsor
- GI Innovation, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 358 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 5
- States / cities
- Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota + 2 more
- Conditions
- Pancreatic Cancer Metastatic
- Interventions
- vilastobart (XTX101), Retifanlimab
- Drug
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2027 – 2030
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Tumors
- Interventions
- Etanercept, Docetaxel, Dexamethasone
- Drug
- Lead sponsor
- Ohio State University Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2000 – 2005
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
- Conditions
- Recurrent Glioblastoma, Glioblastoma, Glioma, Malignant
- Interventions
- CUE-102
- Biological
- Lead sponsor
- David Reardon, MD
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 2
- States / cities
- Boston, Massachusetts
- Conditions
- Glioblastoma Multiforme, Anaplastic Astrocytoma
- Interventions
- Toca 511, Toca FC, Lomustine, Temozolomide, Bevacizumab
- Biological · Drug
- Lead sponsor
- Tocagen Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 403 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 50
- States / cities
- Phoenix, Arizona • Irvine, California • La Jolla, California + 41 more
- Conditions
- Multiple Sclerosis, Relapsing-Remitting
- Interventions
- Cyclophosphamide, Mesna, rATG, Methylprednisolone, G-CSF, IVIg, Autologous Stem Cells
- Drug · Biological
- Lead sponsor
- Northwestern University
- Other
- Eligibility
- 18 Years to 58 Years
- Enrollment
- 66 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Pancreatitis, Chronic; Diabetes; Transplant
- Interventions
- etanercept, Alpha 1-Antitrypsin
- Drug
- Lead sponsor
- University of Minnesota
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 43 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2025
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Solid Tumor
- Interventions
- haNK™ for Infusion
- Biological
- Lead sponsor
- ImmunityBio, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 1
- States / cities
- El Segundo, California
- Conditions
- Metastatic HER2 Positive Gastroesophageal Junction Cancer
- Interventions
- CYNK-101, Pembrolizumab, Trastuzumab, Recombinant Human Interleukin-2, Cyclophosphamide, Fludarabine, Mesna
- Biological · Drug
- Lead sponsor
- Celularity Incorporated
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 3
- States / cities
- La Jolla, California • Washington D.C., District of Columbia • Hackensack, New Jersey
- Conditions
- Advanced Solid Tumors
- Interventions
- GS-3583, Zimberelimab, Cisplatin, Carboplatin, 5-Fluorouracil, Docetaxel
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 4
- States / cities
- Grand Rapids, Michigan • New York, New York • Portland, Oregon + 1 more
- Conditions
- Hemophilia A Without Inhibitor
- Interventions
- Eloctate Injectable Product, Emicizumab Injection [Hemlibra]
- Drug
- Lead sponsor
- Margaret Ragni
- Other
- Eligibility
- 4 Months to 4 Years · Male only
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 3
- States / cities
- Little Rock, Arkansas • Pittsburgh, Pennsylvania
- Conditions
- Solid Tumors, Adult, Multiple Myeloma, Lymphoma
- Interventions
- VP301
- Drug
- Lead sponsor
- Virtuoso BINco, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 1
- States / cities
- San Antonio, Texas
- Conditions
- Alzheimer Disease
- Interventions
- NPT088, Placebo
- Drug
- Lead sponsor
- Proclara Biosciences, Inc.
- Industry
- Eligibility
- 50 Years to 85 Years
- Enrollment
- 83 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2019
- U.S. locations
- 23
- States / cities
- Costa Mesa, California • Fullerton, California • Long Beach, California + 20 more
- Conditions
- Healthy Volunteers
- Interventions
- Efprezimod alfa, Saline
- Biological · Drug
- Lead sponsor
- Oncoimmune, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014 – 2015
- U.S. locations
- 1
- States / cities
- Cincinnati, Ohio
- Conditions
- Advanced Solid Tumor, Refractory Non-Hodgkin Lymphoma
- Interventions
- HCB101
- Drug
- Lead sponsor
- FBD Biologics Limited
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2029
- U.S. locations
- 4
- States / cities
- Port Saint Lucie, Florida • Huntersville, North Carolina • Greenville, South Carolina + 1 more